Metraipolis › archive › dc_07d180e759e2

Characterization of the VHH-Fc construct rimteravimab in healthy adults and patients hospitalized for mild-to-moderate COVID-19: Two Phase 1 randomized… — Europe PMC PMID:42213671

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42213671
DOI
10.1371/journal.pmed.1004609
License (as archived)
solo-consultazione
Archived
2026-11-01T04:17:55.800Z
SHA-256 of the archived text
d65dc0d5314a6d70e78c0a69e6e6c1884275f1780c3d1489a011a4f04748efb8
Stable URL of this page
https://metraipolis.com/documento/dc_07d180e759e2

How to cite

Characterization of the VHH-Fc construct rimteravimab in healthy adults and patients hospitalized for mild-to-moderate COVID-19: Two Phase 1 randomized… — Europe PMC PMID:42213671 — Europe PMC (en), https://europepmc.org/article/MED/42213671 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_07d180e759e2 (Metraipolis archive dc_07d180e759e2, sha256 d65dc0d5314a6d70e78c0a69e6e6c1884275f1780c3d1489a011a4f04748efb8)
BibTeX
@misc{dc07d180e759e2,
  title = {Characterization of the VHH-Fc construct rimteravimab in healthy adults and patients hospitalized for mild-to-moderate COVID-19: Two Phase 1 randomized… — Europe PMC PMID:42213671},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42213671},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_07d180e759e2; sha256 d65dc0d5314a6d70e78c0a69e6e6c1884275f1780c3d1489a011a4f04748efb8},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42213671. Agents can read the archived copy with the MCP tool read_document.